Plasma NGAL in APN Patients
Completed
- Conditions
- Pyelonephritis
- Registration Number
- NCT06802796
- Lead Sponsor
- Kafrelsheikh University
- Brief Summary
In recent years, novel biomarkers of renal dysfunction have attracted attention for the diagnosis of UTIs. NGAL is a 25 kDa protein that belongs to the lipocalin. It acts as a transporter for small hydrophobic molecules and is involved in many physiological processes, such as modulating inflammation, innate immune response, and maintaining metabolic homeostasis
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 120
Inclusion Criteria
- above 20 years Suspected have pyelonphirtis
Exclusion Criteria
- age below 20
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Result of plasma NGAL test One day Result of serum test of NGAL
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does NGAL expression correlate with inflammatory pathways in acute pyelonephritis pathogenesis?
What is the diagnostic accuracy of plasma NGAL compared to CRP and urine culture in APN detection?
Do NGAL levels predict severity or treatment response in acute pyelonephritis subtypes?
How do plasma NGAL dynamics inform early detection of treatment complications in APN patients?
Are other lipocalin family members synergistic with NGAL as UTI biomarkers in renal dysfunction?
Trial Locations
- Locations (1)
Elsayed Abdelhalim Elsayed
🇪🇬Zagazig, Egypt
Elsayed Abdelhalim Elsayed🇪🇬Zagazig, Egypt